Stock
Daily Margin Trading Facility book for Alivus Life Sciences across NSE and BSE, from 20 Jan 2025. All figures in ₹ crore, derived from exchange public disclosures.
What is Alivus Life Sciences’s MTF book?
Alivus Life Sciences Limited (ALIVUS) has ₹26 crore funded under Margin Trading Facility across NSE and BSE as of 23 Oct 2026 — 0.02% of India’s MTF book, ranking #918. Over 1M (the last 30 trading days) the funded value has fallen 11.7%, with the number of shares under margin down 12.5%.
Funded value
₹26 Cr
as of 23 Oct 2026
Rank in book
#918
328 days tracked
Share of book
0.02%
of the whole NSE + BSE book
Peak funded
₹38 Cr
on 16 Sep 2026
Largest single-day addition
+₹12 Cr
on 02 Sep 2026
Largest single-day unwind
−₹4 Cr
on 16 Feb 2026
Free-float market cap
₹3,862 Cr
full market cap ₹15,354 Cr · 25.1% free float · Small cap
MTF share of free float
0.64%
0.3× the median small cap · 0.8× the Health Technology median
Share of free float on margin, month by month
Shares under margin at each month-end as a share of free-float shares, using that month-end’s share count and the free-float filing public at the time. It counts shares, not value, so a price move does not move it by itself.
View as table: share of free float on margin18 months
| Month-end | % of free float |
|---|---|
| 23 Oct 2026 | 0.638% |
| 30 Sep 2026 | 0.826% |
| 07 Apr 2026† | 0.439% |
| 30 Mar 2026 | 0.468% |
| 27 Feb 2026 | 0.479% |
| 30 Jan 2026 | 0.553% |
| 31 Dec 2025 | 0.644% |
| 28 Nov 2025 | 0.666% |
| 31 Oct 2025 | 0.720% |
| 30 Sep 2025 | 0.719% |
| 29 Aug 2025 | 0.663% |
| 31 Jul 2025 | 0.910% |
| 30 Jun 2025 | 0.975% |
| 30 May 2025 | 0.888% |
| 30 Apr 2025 | 0.740% |
| 28 Mar 2025 | 0.745% |
| 28 Feb 2025 | 0.776% |
| 31 Jan 2025 | 1.017% |
† Not the month’s last trading day: the last day the stock was in the archive that month (before 11 Nov 2025 the archive kept only the 500 largest positions).
Dated events
- 20 Jan 2025First recorded in the MTF book
NSE & BSE split
How ALIVUS’s funded book divides across the two exchanges, as of 23 Oct 2026.
NSE ₹25 Cr · 96.1%BSE ₹1 Cr · 3.9%
MTF vs Price
Margin-funded outstanding for ALIVUS in ₹ crore
against the closing price, adjusted for splits and bonuses. Each window uses
the same reference date as the table below, so the two agree. Funded value
moves with the price on its own, so the line under the chart reads the
share count instead — that is what shows whether more stock is
genuinely being borrowed against.
MTF book (₹ Cr)
Close price (₹)
Price and liquidity
Adjusted for splits and bonuses, so a change across a corporate action reflects the market rather than the share count.
Last close
₹1,250.60
as of 23 Oct 2026
Price, 1M
−10.7%
adjusted for splits and bonuses
Delivery, 20-day avg
56.3%
of traded volume actually settled
Sessions to unwind
3
of average deliverable volume
Shares under margin divided by average daily deliverable volume over the last 20 sessions.
Book, shares and price by window
Funded value moves with the price on its own, so the share count is what shows whether more stock is actually being borrowed against. The last column reads the two together.
| Window | Book Δ | Book % | Shares | Price | Reading |
|---|---|---|---|---|---|
| 1D | −₹1 | −3.0% | −3.0% −6,101 | −1.4% | unwinding as it falls |
| 10D | −₹6 | −19.4% | −19.0% −46,313 | −6.5% | unwinding as it falls |
| 1M | −₹3 | −11.7% | −12.5% −28,198 | −8.8% | unwinding as it falls |
| 3M | not enough history | ||||
| 6M | not enough history | ||||
| 1Y | +₹3 | +13.7% | −10.1% −22,018 | +35.8% | unwinding into strength |
Shares under margin
Number of shares funded via MTF over time (NSE + BSE combined).
Rank trajectory
Where ALIVUS has sat in the funded-value ranking each day
(1 = most funded). Lower is more prominent.
ALIVUS — last 30 trading days
Combined NSE + BSE funded value, day-on-day change, share of the whole book, and rank. Newest first.
| Date | Combined (₹ Cr) | Day Δ (₹ Cr) | % of book | Rank |
|---|---|---|---|---|
| 23 Oct 2026 | 26 | −₹1 | 0.02% | 918 |
| 22 Oct 2026 | 26 | +₹0 | 0.02% | 918 |
| 21 Oct 2026 | 26 | −₹1 | 0.02% | 920 |
| 19 Oct 2026 | 27 | −₹0 | 0.02% | 910 |
| 16 Oct 2026 | 28 | −₹3 | 0.02% | 910 |
| 15 Oct 2026 | 30 | +₹0 | 0.02% | 870 |
| 14 Oct 2026 | 30 | −₹0 | 0.02% | 870 |
| 13 Oct 2026 | 30 | −₹1 | 0.02% | 868 |
| 12 Oct 2026 | 31 | +₹0 | 0.02% | 857 |
| 09 Oct 2026 | 31 | −₹0 | 0.02% | 855 |
| 08 Oct 2026 | 32 | −₹0 | 0.02% | 848 |
| 07 Oct 2026 | 32 | −₹0 | 0.02% | 843 |
| 06 Oct 2026 | 32 | +₹0 | 0.02% | 837 |
| 05 Oct 2026 | 32 | −₹0 | 0.02% | 836 |
| 01 Oct 2026 | 33 | −₹1 | 0.02% | 835 |
| 30 Sep 2026 | 33 | −₹2 | 0.02% | 830 |
| 29 Sep 2026 | 35 | +₹1 | 0.02% | 802 |
| 28 Sep 2026 | 35 | −₹0 | 0.02% | 813 |
| 25 Sep 2026 | 35 | −₹0 | 0.02% | 808 |
| 24 Sep 2026 | 35 | −₹0 | 0.02% | 806 |
| 23 Sep 2026 | 35 | +₹1 | 0.02% | 802 |
| 22 Sep 2026 | 35 | −₹0 | 0.02% | 806 |
| 21 Sep 2026 | 35 | +₹0 | 0.02% | 796 |
| 18 Sep 2026 | 35 | −₹1 | 0.02% | 793 |
| 17 Sep 2026 | 36 | −₹2 | 0.02% | 787 |
| 16 Sep 2026 | 38 | +₹2 | 0.02% | 756 |
| 15 Sep 2026 | 36 | +₹2 | 0.02% | 800 |
| 11 Sep 2026 | 34 | +₹1 | 0.02% | 821 |
| 10 Sep 2026 | 33 | +₹0 | 0.02% | 837 |
| 09 Sep 2026 | 33 | — | 0.02% | 836 |
ALIVUS within Health Technology
Ranked #56 of 61 funded Health Technology stocks, carrying 0.4% of that sector’s margin book. Its 0.64% of free float on margin is 0.7× the sector median of 0.90%. Nearest names by funded value:
Disclaimer. Data sourced from daily margin trading disclosure provided by NSE and BSE. This website and page are meant for educational and information only — not investment advice. MTF is leveraged and can amplify losses. Rules, margins, rates and eligible-stock lists change; verify current details with your broker and SEBI/exchange circulars. IndiaMTF.com is not a SEBI-registered intermediary, broker, or investment adviser and has no affiliation with SEBI, NSE or BSE. Figures are reproduced from publicly disclosed exchange data, may be delayed or revised, and should be independently verified before any trading decision. Consult a SEBI-registered investment adviser before investing.